论文部分内容阅读
目的:探讨多西紫杉醇联合消癌平注射液二线治疗晚期NSCLC的效果。方法:统计分析2012年1月至2014年1月我院肿瘤科收治的50例晚期NSCLC患者的临床资料。结果:观察组患者治疗的总有效率28%(7/25)明显比对照组12%(3/25)高;观察组患者的体能状况好转率36%(9/25)明显比对照组12%(3/25)高;观察组患者的白细胞降低、血小板降低、恶心呕吐、肝功能损害Ⅰ度、Ⅱ度、Ⅲ度、Ⅳ度总体发生率明显比对照组低。结论:多西紫杉醇联合消癌平注射液二线治疗晚期NSCLC的效果良好,值得推广。
Objective: To investigate the effect of docetaxel combined with Xiaochangping injection second-line treatment of advanced non-small cell lung cancer. Methods: The clinical data of 50 patients with advanced NSCLC admitted from Department of Oncology in our hospital from January 2012 to January 2014 were statistically analyzed. Results: The total effective rate of observation group was 28% (7/25), which was significantly higher than that of control group (12%, 3/25). The improvement rate of physical ability in observation group was significantly higher than that of control group % (3/25). The overall incidence of grade Ⅰ, Ⅱ, Ⅲ and Ⅳ in the observation group was significantly lower than that in the control group in terms of leukopenia, thrombocytopenia, nausea and vomiting, and liver function damage. Conclusion: Docetaxel combined with Xiao-Ping injection second-line treatment of advanced NSCLC with good results, it is worth promoting.